Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Administration costs of intravenous biologic drugs for rheumatoid arthritis.

Soini EJ, Leussu M, Hallinen T.

Springerplus. 2013 Oct 17;2:531. doi: 10.1186/2193-1801-2-531. eCollection 2013.

2.
3.

Costs of Providing Infusion Therapy for Rheumatoid Arthritis in a Hospital-Based Infusion Center Setting.

Schmier J, Ogden K, Nickman N, Halpern MT, Cifaldi M, Ganguli A, Bao Y, Garg V.

Clin Ther. 2017 Jul 14. pii: S0149-2918(17)30731-2. doi: 10.1016/j.clinthera.2017.06.007. [Epub ahead of print]

PMID:
28716293
4.

A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis.

Nuijten MJ, Engelfriet P, Duijn K, Bruijn G, Wierz D, Koopmanschap M.

Pharmacoeconomics. 2001;19(10):1051-64.

PMID:
11735673
5.

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.

Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. Review.

6.
8.

Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.

Liu Y, Wu EQ, Bensimon AG, Fan CP, Bao Y, Ganguli A, Yang M, Cifaldi M, Mulani P.

Adv Ther. 2012 Jul;29(7):620-34. doi: 10.1007/s12325-012-0035-7. Epub 2012 Jul 27.

PMID:
22843208
9.

Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.

Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ.

J Manag Care Pharm. 2013 Oct;19(8):621-30.

10.

Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany.

Beresniak A, Baerwald C, Zeidler H, Krüger K, Neubauer AS, Dupont D, Merkesdal S.

Clin Exp Rheumatol. 2013 May-Jun;31(3):400-8. Epub 2013 Mar 4.

PMID:
23464803
11.

Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured population.

Curtis JR, Chastek B, Becker L, Quach C, Harrison DJ, Yun H, Joseph GJ, Collier DH.

J Manag Care Spec Pharm. 2015 Apr;21(4):318-29.

12.

[Cost-minimization analysis of subcutaneous abatacept in the treatment of rheumatoid arthritis in Spain].

Ariza R, Van Walsem A, Canal C, Roldán C, Betegón L, Oyagüez I, Janssen K.

Farm Hosp. 2014 Jul 1;38(4):257-65. doi: 10.7399/fh.2014.38.4.1137. Spanish.

13.

Impact of medical practices on the costs of management of rheumatoid arthritis by anti-TNFalpha biological therapy in France.

Fautrel B, Woronoff-Lemsi MC, Ethgen M, Fein E, Monnet P, Sibilia J, Wendling D.

Joint Bone Spine. 2005 Dec;72(6):550-6.

PMID:
15996504
14.

Comparison of Healthcare Costs Between Rheumatoid Arthritis Patients Treated with Infused Biologics After Switching from Another Biologic.

Johnston SS, McMorrow D, Farr AM, Juneau P, Ogale S.

Drugs Real World Outcomes. 2015 Mar;2(1):99-109.

15.

Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis.

Soini EJ, Hallinen TA, Puolakka K, Vihervaara V, Kauppi MJ.

J Med Econ. 2012;15(2):340-51. doi: 10.3111/13696998.2011.649327. Epub 2012 Jan 6.

PMID:
22168785
16.

Use of a validated algorithm to estimate the annual cost of effective biologic treatment for rheumatoid arthritis.

Curtis JR, Schabert VF, Yeaw J, Korn JR, Quach C, Harrison DJ, Yun H, Joseph GJ, Collier D.

J Med Econ. 2014 Aug;17(8):555-66. doi: 10.3111/13696998.2014.914031. Epub 2014 May 14.

PMID:
24754646
17.

Treatment patterns and annual drug costs of biologic therapies across indications from the Humana commercial database.

Howe A, Eyck LT, Dufour R, Shah N, Harrison DJ.

J Manag Care Spec Pharm. 2014 Dec;20(12):1236-44.

18.

Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States.

Yuan Y, Trivedi D, Maclean R, Rosenblatt L.

J Med Econ. 2010 Mar;13(1):33-41. doi: 10.3111/13696990903508021.

PMID:
20001596
19.

Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis.

Sauer BC, Teng CC, He T, Leng J, Lu CC, Walsh JA, Shah N, Harrison DJ, Tang DH, Cannon GW.

J Med Econ. 2016;19(1):34-43. doi: 10.3111/13696998.2015.1086774. Epub 2015 Sep 30.

PMID:
26337538
20.

Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.

Wu N, Lee YC, Shah N, Harrison DJ.

Clin Ther. 2014 Aug 1;36(8):1231-41, 1241.e1-3. doi: 10.1016/j.clinthera.2014.06.014. Epub 2014 Jul 23.

PMID:
25062652

Supplemental Content

Support Center